DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for hereditary ataxia — screening already-approved drugs against its 41-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHereditary ataxia maps to a 41-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hereditary ataxia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tau tubulin kinase 2 (TTBK2) — TTBK2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6VRF · 1.5 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
The hereditary ataxias are a clinically and genetically heterogeneous group of progressive neurodegenerative disorders, and the abstracts provided contain no data on any drug treatment, repurposed or otherwise. The literature reviewed spans from 1995 to 2024 and focuses almost entirely on genetic discovery, classification, and clinical trial readiness, not on therapeutic intervention. One 2016 review states that advances in sequencing have brought the field "to the threshold of meaningful therapies in some but not all of these diseases," but it does not name a single agent. A 1997 German-language review is explicit that "a causal therapy is still missing" for most forms, a statement that remains consistent with the more recent summaries.
The clinical research landscape is described as lagging behind laboratory science. A 2016 review on challenges in clinical research notes that the pace of laboratory research "seems not matched by the pace of clinical research and clinical trial readiness," citing the overall rarity of each individual genetic entity, slow and variable progression, and variable prognosis as obstacles. The same review mentions gene replacement and gene knock-down strategies as possible therapies on the horizon, but these are not drugs in the conventional sense and no efficacy data are presented. A 2012 article on cardiac involvement in hereditary ataxias calls for coordinated clinical trial networks and interdisciplinary care teams, again without reference to any pharmacological treatment.
The remaining abstracts cover cognitive impairment (2024), clinical features and imaging (1995), and the molecular genetics of trinucleotide repeat expansions (1997). None report response rates, survival data, or sample sizes for any intervention. The only concrete therapeutic statement across all abstracts is the 1997 assertion that no causal therapy exists, and the 2016 observation that therapies are only at the threshold in some diseases. There is no evidence here to support any drug repurposing claim for hereditary ataxia.
What is still missing is any clinical trial data whatsoever, any named compound with tested efficacy, and any patient stratification strategy that would allow a rare, genetically diverse population to be enrolled in meaningful numbers. The field lacks not only proven drugs but also the trial infrastructure and outcome measures needed to test them, as the 2016 and 2012 reviews both emphasise.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA Neurology · 2016 · 21 citations · open access
Advances in Sequencing Technologies for Understanding Hereditary Ataxias
AbstractIMPORTANCE: The hereditary progressive ataxias comprise genetic disorders that affect the cerebellum and its connections. Even though these diseases historically have been among the first familial disorders of the nervous system to have been recognized, progress in the field has been challenging because of the large number of ataxic genetic syndromes, many of which overlap in their clinical features. OBSERVATIONS: We have taken a historical approach to demonstrate how our knowledge of the genetic basis of ataxic disorders has come about by novel techniques in gene sequencing and bioinformatics. Furthermore, we show that the genes implicated in ataxia, although seemingly unrelated, appear to encode for proteins that interact with each other in connected functional modules. CONCLUSIONS AND RELEVANCE: It has taken approximately 150 years for neurologists to comprehensively unravel the genetic diversity of ataxias. There has been an explosion in our understanding of their molecular basis with the arrival of next-generation sequencing and computer-driven bioinformatics; this in turn has made hereditary ataxias an especially well-developed model group of diseases for gaining insights at a systems level into genes and cellular pathways that result in neurodegeneration.
Annals of Clinical and Translational Neurology · 2016 · 11 citations · open access
Degenerative Ataxias: challenges in clinical research
AbstractThe degenerative ataxias are a very heterogeneous group of disorders that include numerous genetic diseases as well as apparently "sporadic" entities. There has been an explosion of discoveries related to genetic defects and related pathomechanisms that has brought us to the threshold of meaningful therapies in some but not all of these diseases. There also continues to be lack of knowledge of the causation of disease in a sizeable proportion of these patients. The overall rarity of ataxias as a whole and certainly of the individual genetic entities together with slow and variable progression and variable prognosis in juxtaposition with a rapid development of possible therapies in the horizon such as gene replacement and gene knock-down strategies places the ataxias in a unique position distinct from other similar neurodegenerative diseases. The pace of laboratory research seems not matched by the pace of clinical research and clinical trial readiness. This review summarizes the author's views on the various challenges in translational research in ataxias and hopes to stimulate further thought and discussions on how to bring real help to these patients.
Topical Review: Clinical Aspects of Hereditary Ataxias
AbstractThe hereditary ataxias are a group of complex genetic disorders the understanding of which is undergoing a revolution because of advances in molecular genetics. Within the last few years, at least seven different gene loci have been found to be responsible for these syndromes, and the search is on for additional loci that undoubtedly exist. This review summarizes the clinical features of the various hereditary ataxias with known gene loci, as well as others that are now defined on a clinical basis. It also deals with some of the imaging and neuropharmacologic advances that have been made in this group of disorders.
Fortschritte der Neurologie · Psychiatrie · 1997 · 4 citations
Genetische Diagnostik, Klassifikation und klinische Krankheitsentitäten hereditärer Ataxien
AbstractHereditary ataxias are a heterogeneous group of neurodegenerative diseases. Neither the clinical features nor the findings at autopsy provide a satisfactory basis for the isolation of distinct categories and classification. Recently, several gene loci responsible for inherited ataxias have been identified. For several hereditary ataxias even the disease causing mutations have been described. These findings lead to a new classification of the inherited ataxias based on genotypes rather than pathology or phenotypes. Such a classification will potentially gain wide acceptance since it derives from the molecular genetic cause of the diseases. Furthermore, recent advances in molecular biology improved the understanding of the clinical variability of hereditary ataxias that occurs even within the same family. All forms of progressive dominant ataxias are most likely caused by the same type of mutation: an unstable and expanded trinucleotide repeat. The repeat expansion is moderate in patients with later onset and mild progression but is extensive in juvenile cases with a more rapid course of the disease. Furthermore, the extent of the expansion seems to be at least partially responsible for the development of different phenotypes. The identification of gene loci and mutations allows reliable diagnosis even at a presymptomatic or prenatal stage for an increasing number of inherited ataxias. Although molecular genetics has improved the diagnosis and understanding considerably for most forms of hereditary ataxias a causal therapy is still missing. Therefore, it is essential that presymptomatic analysis is always performed according to the international guidelines. They include genetic counselling by a team of experienced neurologists, geneticists, psychologists and social workers.
AbstractAlthough much attention has been focused on the neurological sequelae of the hereditary ataxias, patients with these conditions also may develop cardiac complications that represent a significant cause of disability and even death. In this article, the authors describe the hereditary ataxias with known cardiac involvement, discuss underlying causes, and review guidelines for screening and treatment. Continued progress will require coordinated clinical trial networks, interdisciplinary care teams, and team science.
Vestnik of North-Eastern Federal University Medical Sciences · 2024 · 2 citations · open access
COGNITIVE IMPAIRMENT IN HEREDITARY ATAXIAS: LITERATURE REVIEW
AbstractHereditary ataxias are a clinically and genetically heterogeneous group of nervous system diseases, mostly progressive and mainly clinically characterized by coordination disorders due to degeneration of the corresponding afferent and efferent neuronal systems. Hereditary ataxias are divided into autosomal dominant, autosomal recessive, and X-linked recessive forms; sporadic forms with unspecified or unknown transmission mechanism are also distinguished. In this article, we review the impact of hereditary ataxias on the cognitive function. We present data from various studies that collectively shed light on the complex relationships between motor and cognitive impairments in patients with hereditary ataxias.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
